Memory cytolytic T-lymphocytes: Induction, regulation and implications for vaccine design

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 711-723

  Baz, Adriana ^a,b   Jackson, David C ^c   Kienzle, Norbert ^a   Kelso, Anne ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Cellular Biology Section   (Uruguay)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvants; CD4+ T cell help; CD8+ T cells; Cross presentation; Cytokines; Dendritic cells; Differentiation; Granzymes; Lipopeptides; Perforin; T cell memory; Toll like receptors; Vaccines

Indexed keywords

ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; LIPOPEPTIDE; LIVE VACCINE; TUMOR ANTIGEN; VACCINE;

CANCER; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG STRUCTURE; EFFECTOR CELL; GENETIC REGULATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GEOMETRY; HUMAN; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STRUCTURE ANALYSIS; VACCINATION; VIRUS INFECTION;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONAL DELETION; CYTOKINES; DRUG DESIGN; HUMANS; IMMUNOLOGIC MEMORY; INFECTION; LIPOPROTEINS; NEOPLASMS; T-LYMPHOCYTE SUBSETS; VACCINES;

EID: 27444447121     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.711     Document Type: Review

References (124)

1. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Ann. Rev. Immunol. 15, 749-795 (1997).
2. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 10, 411-452 (1992).
3. Raja SM, Metkar SS, Froelich CJ. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr. Opin. Immunol. 15, 528-532 (2003).
4. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652 (1994).
5. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32, 1123-1136 (2000).
6. + T-cells. The authors' point of view challenges many of the current dogmas in this field.
7. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T-cell differentiation. Cell 111, 837-851 (2002).
8. + T-cell response. J. Immunol. 161, 674-683 (1998).
9. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177, 134-140 (2000).
10. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired Immunity Nature Immunol. 2, 675-680 (2001).
11. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
12. + T-cells stimulated by virus-induced Type I interferon. Nature Immunol. 4, 1009-1015 (2003).
13. + memory T-cells is highlighted.
14. Andrews DM, Andoniou CE, Scalzo AA et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol. Immunol. 42, 547-555 (2005).
15. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000).
16. Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004). Excellent review of the molecular basis of cross-presentation covering the most important aspects of this process, including the role of different populations of dendritic cells (DCs), the significance of cross-presentation in immunity and the potential use of this pathway of antigen presentation in vaccine design.
17. - dendritic cells cross-prime cytotoxic T-cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
18. Dustin ML. Stop and go traffic to tune T-cell responses. Immunity 21, 305-314 (2004).
19. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nature Rev. Immunol. 3, 973-983 (2003).
20. Gett AV, Sallusto F, Lanzavecchia A, Geginat J. T-cell fitness determined by signal strength. Nature Immunol. 4, 355-360 (2003).
21. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T-cell function. Nature Immunol. 2, 203-209 (2001).
22. Hamann A, Klugewitz K, Austrup F, Jablonski-Westrich D. Activation induces rapid and profound alterations in the trafficking of T-cells. Eur. J. Immunol. 30, 3207-3218 (2000).
23. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Rev. Immunol. 2, 251-262 (2002).
24. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161, 5338-5346 (1998).
25. + T-cells during an acute virus infection. Immunity 8, 167-175 (1998).
26. Zheng L, Fisher G, Miller RE et al. Induction of apoptosis in mature T-cells by tumour necrosis factor. Nature 377, 348-351 (1995).
27. Hildeman DA, Zhu Y, Mitchell TC et al. Activated T-cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16, 759-767 (2002).
28. + T-cell homeostatsis by perforin and interferon-γ. Science 290, 1354-1358 (2000).
29. + T-cell memory determined by clonal burst size. Nature 369, 652-654 (1994).
30. + T-cell response is much less apparent following secondary challenge. J. Virol. 74, 3486-3493 (2000).
31. + T-cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunol. 2, 415-422 (2001).
32. + T-cell can give rise to progeny expressing Type 1 and/or Type 2 cytokine genes and can retain its multipotentiality through many cell divisions. Proc. Natl Acad. Sci. USA 94, 8070-8075 (1997).
33. Gett AV, Hodgkin PD. Cell division regulates the T-cell cytokine repertoire, revealing a mechanism underlying immune class regulation. Proc. Natl Acad. Sci. USA 95, 9488-9493 (1998).
34. low phenotype in the presence of IL-4. J. Immunol. 174, 2021-2029 (2005).
35. - cells that make TH2 cytokines and help B-cells. Science 260, 1802-1805 (1993).
36. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting Type 2 versus Type 1 cytokine profiles. J. Exp. Med. 180, 1715-1728 (1994).
37. Kienzle N, Buttigieg K, Groves P, Kawula T, Kelso A. A clonal culture system demonstrates that IL-4 induces a subpopulation of noncytolytic T-cells with low CD8, perforin, and granzyme expression. J. Immunol. 168, 1672-1681 (2002).
38. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and Type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin. Immunol. 111, 69-81 (2004).
39. Schaller MA, Lundy SK, Huffnagle GB, Lukacs NW. CD8(+) T-cell contributions to allergen induced pulmonary inflammation and airway hyper-reactivity. Eur. J. Immunol. (2005).
40. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous Type 1 antitumor responses. J. Immunol. 172, 1380-1390 (2004).
41. + T-helper Type 2 cells. J. Exp. Med. 181, 5-7 (1995).
42. Lieberman J, Fan Z. Nuclear war: the granzyme A-bomb. Curr. Opin. Immunol. 15, 553-559 (2003).
43. Grossman WJ, Revell PA, Lu ZH et al. The orphan granzymes of humans and mice. Curr. Opin. Immunol. 15, 544-552 (2003).
44. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nature Rev. Immunol. 3, 361-370 (2003).
45. Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15, 533-543 (2003).
46. + T-cells during primary activation. Int. Immunol. 14, 605-613 (2002).
47. Johnson H, Scorrano L, Korsmeyer SJ, Ley TJ. Cell death induced by granzyme C. Blood 101, 3093-3101 (2003).
48. Grossman WJ, Verbsky JW, Tollefsen BL et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104, 2840-2848 (2004).
49. + T-cell populations. Int. Immunol. 11, 617-621 (1999).
50. Bucy RP, Panoskaltsis-Mortari A, Huang GQ et al. Heterogeneity of single cell cytokine gene expression in clonal T-cell populations. J. Exp. Med. 180, 1251-1262 (1994).
51. Chtanova T, Kemp RA, Sutherland AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) Type 1 and Type 2 T-cells. J. Immunol. 167, 3057-3063 (2001).
52. Auphan-Anezin N, Verdeil G, Schmitt-Verhulst AM. Distinct thresholds for CD8 T-cell activation lead to functional heterogeneity: CD8 T-cell priming can occur independently of cell division. J. Immunol. 170, 2442-2448 (2003).
53. + T-cell population isolated from an efifector site contains cells with flexible cytokine profiles. J. Exp. Med. 190, 1081-1092 (1999).
54. Kelso A, Th1 and Th2 subsets: paradigms lost? Immunol. Today 16, 374-379 (1995).
55. low phenotype, an alternative career choice for CD8 T-cells during primary differentiation. Immunol. Cell Biol. 82, 75-83 (2004).
56. Smyth MJ, Street SE, Trapani JA. Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection. J. Immunol. 171, 515-518 (2003).
57. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T-lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
58. Wherry EJ, Teichgraber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T-cell subsets. Nature Immunol. 4, 225-234 (2003).
59. + T-cell lineage commitment. Nature Immunol. 6, 793-799 (2005).
60. Kaech SM, Tan JT, Wherry EJ et al. Selective expression of the interleukin-7 receptor identifies effector CD8 T-cells that give rise to long-lived memory cells. Nature Immunol. 4, 1191-1198 (2003).
61. Madakamutil LT, Christen U, Lena CJ et al. CD8αα-mediated survival and differentiation of CD8 memory T-cell precursors. Science 304, 590-593 (2004).
62. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J. Interleukin-15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T-cells. J. Exp. Med. 196, 935-946 (2002).
63. + T-cells. J. Immunol 155, 1873-1883 (1995).
64. Harrington LE, Galvan M, Baum LG, Altman JD, Ahmed R. Differentiating between memory and effector CD8 T-cells by altered expression of cell surface O-glycans. J. Exp. Med. 191, 1241-1246 (2000).
65. + T-cells. J. Immunol. 164, 3950-3954 (2000).
66. Sun JC, Bevan MJ. Defective CD8 T-cell memory following acute infection without CD4 T-cell help. Science 300, 339-342 (2003).
67. + T-cells. J. Exp. Med. 188, 103-117 (1998).
68. Agarwal S, Rao A. Modulation of chromatin structure regulates cytokine gene expression during T-cell differentiation. Immunity 9, 765-775 (1998).
69. + T-lymphocytes. J. Immunol. 162, 5053-5057 (1999).
70. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T-lymphocytes. Science 283, 1745-1748 (1999).
71. Lauvau G, Vijh S, Kong P et al. Priming of memory but not effector CD8 T-cells by a killed bacterial vaccine. Science 294, 1735-1739 (2001).
72. Manjunath N, Shankar P, Wan J et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T-lymphocytes. J. Clin. Invest. 108, 871-878 (2001).
73. Holmes S, He M, Xu T, Lee PP. Memory T-cells have gene expression patterns intermediate between naïve and effector. Proc. Natl Acad. Sci. USA 102, 5519-5523 (2005).
74. + T-lymphocytes. Nature 421, 852-856 (2003).
75. Shedlock DJ, Shen H. Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science 300, 337-339 (2003).
76. + T-cell memory. Science 297, 2060-2063 (2002).
77. Marzo AL, Vezys V, Klonowski KD et al. Fully functional memory CD8 T-cells in the absence of CD4 T-cells. J. Immunol. 173, 969-975 (2004).
78. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478 (1998).
79. Bennett SR, Carbone FR, Karamalis F et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
80. Borrow P, Tough DF, Eto D et al. CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T-lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J. Virol. 72, 7440-7449 (1998).
81. + memory T-cell subsets. Proc. Natl Acad. Sci. USA 101, 5610-5615 (2004).
82. Sun JC, Bevan MJ. Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T-cells. J. Immunol. 172, 3385-3389 (2004).
83. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93 (2005).
84. Bellier B, Thomas-Vaslin V, Saron MF, Klatzmann D. Turning immunological memory into amnesia by depletion of dividing T-cells. Proc. Natl Acad. Sci. USA 100, 15017-15022 (2003).
85. + T-cells. J. Exp. Med. 195, 1515-1522 (2002).
86. Marks-Konczalik J, Dubois S, Losi JM et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl Acad. Sci. USA 97, 11445-11450 (2000).
87. + cells. J. Exp. Med. 195, 1523-1532 (2002).
88. + T-cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
89. + memory cell homeostasis. J. Immunol. 173, 3801-3809 (2004).
90. Esser MT, Marchese RD, Kierstead LS et al. Memory T-cells and vaccines. J. Clin. Invest. 21, 419-430 (2003).
91. Kalos M. Tumor antigen-specific T-cells and cancer immunodierapy: current issues and future prospects. J. Clin. Invest. 21, 781-786 (2003).
92. Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25, 92-97 (2004). Comprehensive review of different intracellular pathways leading to the presentation of pep tides in association with major histocompatibility complex (MHC) class I molecules. In addition to the classic endogeneous presentation pathway, pathogen components can access MHC class I molecules by other means. Such alternative mechanisms are clearly explained and their implications for vaccine development are discussed.
93. Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus. Immunity Nature 415, 331-335 (2002).
94. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ. Live bacteria as the basis for immunotherapies against cancer. Expert. Rev. J. Clin. Invests. 1, 495-505 (2002).
95. Liu M, Acres B, Balloul JM et al. Gene-based vaccines and immunotherapeutics. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14567-14571 (2004).
96. Tartour E, Ciree A, Haicheur N, Benchetrit F, Fridman WH. Development of non-live vectors and procedures (liposomes, pseudoviral particles, toxin, beads, adjuvantsellipsis) as tools for cancer vaccines. Immunol. Lett. 74, 45-50 (2000).
97. Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol. 15, 513-517 (2004).
98. O'Neill D, Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 109, 1-18 (2005).
99. + T-cell Immunity J. Virol. 76, 3791-3799 (2002).
100. Harvey TJ, Anraku I, Linedale R et al. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J. Virol. 77, 7796-7803 (2003).
101. Estcourt MJ, Ramsay AJ, Brooks A et al. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T-lymphocyte population. Int. Immunol. 14, 31-37 (2002).
102. Woodberry T, Gardner J, Elliott SL et al. Prime boost vaccination strategies: CD8 T-cell numbers, protection, and Th1 bias. J. Immunol. 170, 2599-2604 (2003).
103. Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T-cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171, 1815-1820 (1990).
104. Ghosh S, Walker J, Jackson DC. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104, 58-66 (2001).
105. + T-cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes. Eur. J. Immunol. 35, 806-815 (2005).
106. Neumann F, Wagner C, Stevanovic S et al. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int. J. Cancer 112, 661-668 (2004).
107. Jackson DC, Lau YF, Le T et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T-cell responses. Proc. Natl Acad. Sci. USA 101, 15440-15445 (2004).
108. Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert. Rev. J. Clin. Invests. 1, 207-213 (2002).
109. BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect. Immun. 72, 4376-4384 (2004).
110. Brown LE, Jackson DC. Lipid-based self-adjuvanting vaccines. Curr. Drug Delivery (2005). Focuses on the use of lipopeptides as immunogens to induce antibody and cytotoxic T-lymphocyte responses. The authors discuss key issues that can affect the immunogenicity of lipopeptides, such as the nature of the lipid, spatial distribution of epitopes and incorporation of T-helper epitopes. Mechanisms of action and their potential clinical applications of lipopeptides are extensively discussed.
111. Zauner W, Lingnau K, Mattner F, von Gabain A, Buschle M. Defined synthetic vaccines. Biol. Chem. 382, 581-595 (2001).
112. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T-lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561-564 (1989).
113. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T-cells. Eur. J. Immunol. 21, 2649-2654 (1991).
114. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 169, 4905-4912 (2002).
115. Ridgely SL, Zhang B, McGuire TC. Response of ELA-Al horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge. J. Clin. Invest. 21, 491-506 (2003).
116. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2, 425-431 (2002).
117. Zeng W, Jackson DC, Murray J, Rose K, Brown LE. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. J. Clin. Invest. 18, 1031-1039 (2000).
118. Deliyannis G, Jackson DC, Ede NJ et al. Induction of long-term memory CD8(+) T-cells for recall of viral clearing responses against influenza virus. J. Virol. 76, 4212-4221 (2002).
119. Zeng W, Ghosh S, Macris M, Pagnon J, Jackson DC. Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. J. Clin. Invest. 19, 3843-3852 (2001).
120. Fitzmaurice CJ, Brown LE, Kronin V, Jackson DC. The geometry of synthetic peptide-based immunogens affects the efficiency of T-cell stimulation by professional antigen-presenting cells. Int. Immunol. 12, 527-535 (2000).
121. Tsunoda I, Sette A, Fujinami RS et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. J. Clin. Invest. 17, 675-685 (1999).
122. Chua BY, Healy A, Cameron PU et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol. Cell Biol. 81, 67-72 (2003).
123. Hosmalin A, Andrieu M, Loing E et al. Lipopeptide presentation pathway in dendritic cells. Immunol. Lett. 79, 97-100 (2001).
124. Terabe M, Berzofsky JA. Immunoregulatory T-cells in tumor Immunity Curr. Opin. Immunol. 16, 157-162 (2004).